Imeglimin

Imeglimin

Names
IUPAC name (2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
Identifiers
CAS Registry Number	775351-65-0
ChemSpider	26232690
InChI InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1 Key: GFICWFZTBXUVIG-SCSAIBSYSA-N InChI=1/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1 Key: GFICWFZTBXUVIG-SCSAIBSYBC
Jmol-3D images	Image
SMILES C[C@H]1NC(=NC(=N1)N)N(C)C
Properties
Molecular formula	C6H13N5
Molar mass	155.20 g·mol−1
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Imeglimin is an experimental drug being developed as an oral anti-diabetic. It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It will be the first of a new class of anti-diabetic if it is approved.

Imeglimin is in development (completed phase IIb clinical trials) for use both as monotherapy and in combination with other type-2 diabetes treatments.^[1][2]

Various research protocols are being known through various scientists. Early studies showed that imeglimin is as effective as metformin in regulating glycaemic control.^[3]

References